Completed

Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Extended release naltrexone

+ Placebo

Drug
Who is being recruted

From 18 to 55 Years
See all eligibility criteria
How is the trial designed

Other Study

Placebo-Controlled
Interventional
Study Start: May 2013
See protocol details

Summary

Principal SponsorOregon Health and Science University
Last updated: March 5, 2019
Sourced from a government-validated database.Claim as a partner

Study start date: May 1, 2013

Actual date on which the first participant was enrolled.

The purpose of this protocol is to learn more about impulsive decision making in people who use methamphetamines. The investigators would like to know if a medication called naltrexone changes how people make decisions. The investigators would also like to know whether changes in decision making can be observed by MRI (magnetic resonance imaging). The research is conducted in Portland, OR.

NCT01822132
Principal SponsorOregon Health and Science University
Last updated: March 5, 2019
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

76 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Other Study

Some studies explore topics that don't fall into a specific category. These might include innovative research, new technologies, or emerging healthcare areas.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 55 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

Summary Inclusion Criteria: Diagnostic and Statistical Manual (DSM)-IV Methamphetamine Dependence Deemed healthy enough to participate by study physician Age 18-55 Right handed English-speaking Summary Exclusion Criteria: Current opioid use in the last 30 days; opioid abuse or dependence within past 5 years Pregnancy MRI contraindications (e.g. metal in head). The research is conducted in Portland, OR.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
One dose of intramuscular injection of 380mg extended-release naltrexone.

Group II

Placebo
One dose of intramuscular injection of placebo.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 2 locations

Oregon Health & Science University

Portland, United StatesOpen Oregon Health & Science University in Google Maps

Portland VA Medical Center

Portland, United States
Completed2 Study Centers